Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $349.29 | $7.21 | 4,744.26% | 6,985.80x | 335.82x | 7.74x | 9.37x | 18.68x | $529.27M | 1.38% | $4.13B | 37.48 | $36.56B | 114.95 | ||
| CORT | CORCEPT THERAPEUTICS INC | $75.05 | $32.38 | 131.78% | 75.05x | 73.76x | 10.48x | 12.49x | 1.04x | $162.57M | 2.09% | $631.90M | 6.10 | $7.78B | 117.85 | ||
| NVO | NOVO NORDISK A S | $47.60 | $150.02 | -68.27% | 13.24x | 1.99x | 4.35x | 8.08x | 0.14x | $9.34B | 4.42% | $26.18B | 5.89 | $222.16B | 8.95 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $445.79 | $28.75 | 1,450.71% | 1,438.03x | 306.20x | 18.25x | 251.80x | 6.12x | $221.36M | 0.38% | $233.89M | 1.78 | $60.62B | 399.00 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $1.74 | $4.95 | -64.88% | 24.86x | 13.25x | 2.23x | 2.64x | 0.14x | -$11.69M | -8.45% | $52.91M | 0.67 | $134.46M | 15.16 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $9.05 | $11.21 | -19.24% | 18.85x | 7.38x | 6.00x | 3.83x | 0.40x | -$23.64M | -4.67% | $133.17M | 2.38 | $517.77M | 7.70 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $41.49 | $14.99 | 176.80% | 84.67x | 39.20x | 5.18x | 5.87x | 1.26x | $101.73M | 3.28% | $535.38M | 7.17 | $2.98B | 55.61 | ||
| GMAB | GENMAB A | $30.04 | $113.62 | -73.56% | 12.82x | 1.73x | 5.41x | 3.35x | 0.11x | $1.19B | 6.19% | $5.75B | 8.96 | $17.67B | 8.83 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $199.03 | $60.99 | 226.34% | 86.16x | 28.42x | 15.51x | 4.12x | 1.55x | $30.76M | 0.79% | $950.17M | 48.53 | $4.23B | 41.05 | ||
| ARGX | ARGENX SE | $918.50 | $255.77 | 259.11% | 36.70x | 54.89x | 29,629.03x | 7.82x | 3.07x | $467.72M | 0.83% | $7.17B | 117.50 | $53.66B | 66.14 | ||
| VCEL | VERICEL CORP | $37.85 | $7.22 | 424.31% | 145.58x | 168.67x | 7.39x | 5.95x | 2.45x | $20.38M | 1.07% | $321.86M | 6.38 | $1.91B | 65.23 | ||
| RPRX | ROYALTY PHARMA PLC | $38.39 | $41.36 | -7.17% | 21.81x | 8.38x | 7.06x | 2.30x | 0.46x | $2.11B | 12.74% | $9.62B | 22.28 | $30.17B | 28.89 | ||
| TECH | BIO-TECHNE CORP | $58.73 | $16.13 | 264.08% | 117.46x | 28.74x | 7.50x | 4.66x | 1.64x | $224.06M | 2.45% | $1.97B | 12.65 | $9.40B | 42.56 | ||
| KRYS | KRYSTAL BIOTECH INC | $204.23 | $83.37 | 144.96% | 29.60x | 40.09x | 15.84x | 5.20x | 1.74x | $166.02M | 2.81% | $1.14B | 39.30 | $5.54B | 28.66 | ||
| HALO | HALOZYME THERAPEUTICS INC | $68.97 | $76.31 | -9.62% | 14.10x | 10.98x | 6.50x | 16.10x | 0.53x | $602.40M | 7.45% | $503.92M | 4.30 | $9.20B | 10.88 | ||
| MDXG | MIMEDX GROUP INC | $6.55 | $3.59 | 82.62% | 23.39x | 15.11x | 2.46x | 4.06x | 1.24x | $66.82M | 6.89% | $238.95M | 1.61 | $846.20M | 12.23 | ||
| GYRE | GYRE THERAPEUTICS INC | $7.49 | $0.85 | 784.02% | 107.00x | 71.06x | 6.34x | 7.08x | 6.28x | $3.05M | 0.45% | $101.92M | 1.12 | $682.30M | 51.58 | ||
| VCYT | VERACYTE INC | $40.85 | $8.83 | 362.70% | 104.74x | 102.25x | 6.50x | 2.57x | 2.30x | $98.21M | 3.06% | $1.26B | 15.98 | $2.95B | 51.80 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $52.48 | $41.63 | 26.07% | 19.29x | 17.28x | 3.26x | 1.66x | 0.75x | $832.13M | 8.26% | $6.06B | 31.54 | $9.43B | 12.20 | ||
| CRMD | CORMEDIX INC | $9.72 | $16.49 | -41.07% | 4.28x | 4.59x | 3.44x | 2.05x | 1.08x | $74.42M | 10.08% | $374.13M | 4.93 | $866.26M | 7.72 | ||
| INCY | INCYTE CORP | $101.76 | $66.46 | 53.11% | 16.85x | 14.61x | 4.14x | 4.30x | 1.20x | $1.20B | 6.01% | $4.65B | 23.77 | $17.56B | 10.43 | ||
| INVA | INNOVIVA INC | $21.16 | $18.06 | 17.15% | 11.20x | 17.78x | 3.76x | 1.57x | 1.10x | $196.54M | 13.45% | $1.01B | 14.63 | $1.36B | 6.35 | ||
| ADMA | ADMA BIOLOGICS INC | $16.36 | $9.22 | 77.36% | 18.59x | 27.03x | 7.99x | 9.03x | 1.47x | $40.73M | 1.05% | $431.19M | 1.81 | $3.91B | 22.69 | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $15.14 | $7.08 | 113.74% | 26.10x | 22.89x | 7.51x | 5.46x | 1.51x | $119.87M | 6.00% | $365.77M | 2.78 | $2.00B | 19.33 | ||
| EXEL | EXELIXIS INC | $41.78 | $27.05 | 54.46% | 16.98x | 17.43x | 4.90x | 5.18x | 1.21x | $779.77M | 6.95% | $2.16B | 8.05 | $11.00B | 11.86 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $422.32 | $171.63 | 146.06% | 29.51x | 22.98x | 9.21x | 6.19x | 1.76x | $3.34B | 3.09% | $17.32B | 67.76 | $104.05B | 22.32 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $33.39 | $39.37 | -15.19% | 10.34x | 10.22x | 2.33x | 2.30x | 0.60x | $296.89M | 15.45% | $835.12M | 14.51 | $1.44B | 5.36 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $737.00 | $347.18 | 112.28% | 16.96x | 17.24x | 5.36x | 2.50x | 2.87x | $4.22B | 5.53% | $30.96B | 298.82 | $77.66B | 13.59 | ||
| UTHR | UNITED THERAPEUTICS CORP | $474.72 | $192.51 | 146.59% | 16.67x | 16.90x | 6.65x | 3.10x | 6.44x | $1.12B | 5.40% | $6.59B | 150.46 | $19.10B | 10.77 | ||
| MNKD | MANNKIND CORP | $4.97 | $1.27 | 292.14% | 49.70x | 52.48x | 4.86x | -34.26x | 2.68x | $43.39M | 2.84% | -$44.55M | -0.15 | $1.76B | 24.03 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $22.77 | $10.78 | 111.26% | 12.72x | 15.31x | 4.83x | 3.04x | 21.47x | $234.54M | 8.40% | $920.25M | 7.51 | $2.11B | 6.52 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.